Empagliflozin Treatment for Patients with Heart Failure with Preserved Ejection Fraction-A Systematic Review

Abstract

Objective: The goal of this systematic review is to determine the effectiveness of empagliflozin in managing patients with heart failure with preserved ejection fraction (HFpEF) as compared with a placebo. Methods: Web of Science, Cochrane, PubMed, and Scopus databases were searched for articles from 2000 to November 2022. Reference lists of articles were manually screened. Trials that recruited patients with HFpEF and reported the effects of empagliflozin were included. Endnote X9 software was used for study screening process. Results: 14 papers out of 1235 found were selected for full-text reviews. The systematic review included nine papers that were all randomized controlled trials. According to the findings of individual trials, empagliflozin is more effective and has a statistically insignificant safety advantage over a placebo. Conclusion: Empagliflozin treatment for HFpEF patients appears to be both safe and efficient when compared to a placebo, according to data of moderate quality